204 related articles for article (PubMed ID: 34661709)
1. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.
Nickles E; Dharmadhikari B; Yating L; Walsh RJ; Koh LP; Poon M; Tan LK; Wang LZ; Ang Y; Asokumaran Y; Chong WQ; Huang Y; Loh KS; Tay J; Soo R; Koh M; Ho LP; Chan M; Niam M; Soh M; Luah YH; Lim CM; Kaliaperumal N; Au VB; Talib NBSN; Sng R; Connolly JE; Goh BC; Schwarz H
Cancer Immunol Immunother; 2022 Jun; 71(6):1531-1543. PubMed ID: 34661709
[TBL] [Abstract][Full Text] [Related]
2. CD137L-DCs, Potent Immune-Stimulators-History, Characteristics, and Perspectives.
Zeng Q; Zhou Y; Schwarz H
Front Immunol; 2019; 10():2216. PubMed ID: 31632390
[TBL] [Abstract][Full Text] [Related]
3. Methods for generating the CD137L-DC-EBV-VAX anti-cancer vaccine.
Nickles E; Xia R; Sun R; Schwarz H
Methods Cell Biol; 2024; 183():187-202. PubMed ID: 38548412
[TBL] [Abstract][Full Text] [Related]
4. CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8
Dharmadhikari B; Nickles E; Harfuddin Z; Ishak NDB; Zeng Q; Bertoletti A; Schwarz H
Cancer Immunol Immunother; 2018 Jun; 67(6):893-905. PubMed ID: 29508025
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors.
Prasad M; Ponnalagu S; Zeng Q; Luu K; Lang SM; Wong HY; Cheng MS; Wu M; Mallilankaraman K; Sobota RM; Lim YT; Wang LC; Goh CK; Tay KXJ; Loh KS; Wang CI; Lee WH; Goh BC; Lim CM; Schwarz H
Cancer Immunol Immunother; 2022 Nov; 71(11):2583-2596. PubMed ID: 35299256
[TBL] [Abstract][Full Text] [Related]
6. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy.
Smith C; Tsang J; Beagley L; Chua D; Lee V; Li V; Moss DJ; Coman W; Chan KH; Nicholls J; Kwong D; Khanna R
Cancer Res; 2012 Mar; 72(5):1116-25. PubMed ID: 22282657
[TBL] [Abstract][Full Text] [Related]
7. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
[TBL] [Abstract][Full Text] [Related]
8. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
[TBL] [Abstract][Full Text] [Related]
10. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy.
Li F; Song D; Lu Y; Zhu H; Chen Z; He X
J Immunother; 2013 Apr; 36(3):208-14. PubMed ID: 23502768
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
[TBL] [Abstract][Full Text] [Related]
12. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y
Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320
[TBL] [Abstract][Full Text] [Related]
13. Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.
Hua L; Chen S; Wei M; Shen Y; Long J; Lin Z; Meng Y; Guo C; Huang H; Tu X; Yao M
Cancer Biother Radiopharm; 2022 Feb; 37(1):2-10. PubMed ID: 33764811
[No Abstract] [Full Text] [Related]
14. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma.
Li W; Duan X; Chen X; Zhan M; Peng H; Meng Y; Li X; Li XY; Pang G; Dou X
Front Immunol; 2022; 13():1079515. PubMed ID: 36713430
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
Liu MZ; Fang SG; Huang W; Wang HY; Tian YM; Huang RD; Sun Z; Zhao C; Lu TX; Huang Y; Han F
Cancer Med; 2019 Aug; 8(10):4633-4643. PubMed ID: 31268626
[TBL] [Abstract][Full Text] [Related]
16. A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma.
Chia WK; Wang WW; Teo M; Tai WM; Lim WT; Tan EH; Leong SS; Sun L; Chen JJ; Gottschalk S; Toh HC
Ann Oncol; 2012 Apr; 23(4):997-1005. PubMed ID: 21821548
[TBL] [Abstract][Full Text] [Related]
17. EBV latent membrane protein 1 augments γδ T cell cytotoxicity against nasopharyngeal carcinoma by induction of butyrophilin molecules.
Liu Y; Lui KS; Ye Z; Fung TY; Chen L; Sit PY; Leung CY; Mak NK; Wong KL; Lung HL; Tanaka Y; Cheung AKL
Theranostics; 2023; 13(2):458-471. PubMed ID: 36632221
[TBL] [Abstract][Full Text] [Related]
18. Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma.
Secondino S; Pedrazzoli P; Basso S; Bossi P; Bianco A; Imarisio I; Pagani A; De Cicco M; Muscianisi S; Casanova M; Morosi C; Bergamini C; Benazzo M; Cossu Rocca M; Perotti C; Baldanti F; Zecca M; Licitra LF; Comoli P
Front Immunol; 2023; 14():1208475. PubMed ID: 37497213
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
Zhang Y; Tang LL; Li YQ; Liu X; Liu Q; Ma J
Int J Cancer; 2019 May; 144(9):2313-2319. PubMed ID: 30485420
[TBL] [Abstract][Full Text] [Related]
20. Regulation of myelopoiesis by CD137L signaling.
Tang Q; Jiang D; Harfuddin Z; Cheng K; Moh MC; Schwarz H
Int Rev Immunol; 2014; 33(6):454-69. PubMed ID: 24941289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
